An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn's Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.

Trial Profile

An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn's Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Mundipharma Pharmaceuticals BV
  • Most Recent Events

    • 09 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top